Would that delay not open a window for a competitor to file some relevant IP? Or would no one outside GILD have access to molecular structure even though the drug was given to patients?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.